<DOC>
	<DOCNO>NCT01596270</DOCNO>
	<brief_summary>Primary Objective : - To evaluate safety tolerability SAR245409 tablet administer twice day patient solid tumor lymphoma . Secondary Objectives : - To evaluate blood level SAR245409 administration SAR245409 tablet twice day patient solid tumor lymphoma . - To evaluate effect food blood level SAR245409 administration SAR245409 tablets patient solid tumor lymphoma . - To evaluate effect SAR245409 body administration SAR245409 tablet twice day patient solid tumor lymphoma . - To obtain information SAR245409 administer twice day patient solid tumor lymphoma affect disease symptom study treatment side effect report patient questionnaire . - To explore antitumor activity SAR245409 tablet administer twice day patient solid tumor lymphoma .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics SAR245409 Tablets Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>The total study duration per patient 58 128 day include screening period ( 1 28 day ) , food interaction investigation period ( applicable ; 4 11 day ) , two 28-day treatment cycle ( 56 day ) , end-of-treatment visit ( within 7 day last SAR245409 administration ) follow-up visit ( within 30 Â± 3 day last SAR245409 administration ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Solid tumor metastatic unresectable , relapsed refractory lymphoma ( include chronic lymphocytic leukemia/small lymphocytic lymphoma ) , standard therapy longer effective therapy know prolong survival . Male female patient &gt; = 18 year old . Eastern Cooperative Oncology Group Performance Status &lt; = 1 . Adequate white blood cell , platelet haemoglobin . Adequate liver kidney function . Fasting plasma glucose &lt; 160 mg/dL . No malignancy . Women childbearing potential use adequate contraception . Exclusion criterion : History partial full gastrectomy . Lymphoma involve gastrointestinal tract . Uncontrolled brain metastasis primary brain tumor . Prior treatment cytotoxic chemotherapy ( include investigational agent ) biologic agent ( antibody , immune modulators , cytokine ) within 4 week , nitrosoureas mitomycin C within 6 week , first dose study treatment . Prior treatment smallmolecule kinase inhibitor ( include investigational agent ) within 2 week , 5 half life drug active metabolite , whichever longer , first dose study treatment . Any investigational therapy within 4 week first dose study treatment . Prior anticancer hormonal therapy within 1 week first dose study treatment . Prior radiation therapy within 2 week first dose study treatment . Intolerance prior treatment PI3K inhibitor . Hereditary acquire immunodeficiency syndrome HIV ( human immunodeficiency virus ) infection . Lymphoma patient positive serology Hepatitis B surface antigen ( HBsAg ) antiHepatitis C virus ( antiHCV ) antibody . Positive serology Hepatitis B surface antigen ( HBsAg ) antiHepatitis C virus ( antiHCV ) antibody . Patient pregnant breastfeeding . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>